NASDAQ:SWAVShockwave Medical Stock Price, Forecast & News

Shockwave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SWAV shares have increased by 28.1% and is now trading at $44.11. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Shockwave Medical.

Shockwave Medical is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Shockwave Medical.

Shockwave Medical Inc (NASDAQ:SWAV) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.10. The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.17 million. Shockwave Medical had a negative return on equity of 38.18% and a negative net margin of 112.25%. The company's quarterly revenue was up 109.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.37) EPS. View Shockwave Medical's earnings history.

7 Wall Street analysts have issued 1 year price objectives for Shockwave Medical's shares. Their forecasts range from $23.00 to $50.00. On average, they anticipate Shockwave Medical's stock price to reach $42.57 in the next year. This suggests that the stock has a possible downside of 3.5%. View analysts' price targets for Shockwave Medical.

Media stories about SWAV stock have trended extremely negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Shockwave Medical earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutShockwave Medical.

Shockwave Medical saw a increase in short interest in April. As of April 30th, there was short interest totaling 3,970,000 shares, an increase of 12.5% from the April 15th total of 3,530,000 shares. Based on an average trading volume of 496,600 shares, the short-interest ratio is currently 8.0 days. Approximately 16.3% of the company's stock are sold short. View Shockwave Medical's Current Options Chain.

Some companies that are related to Shockwave Medical include Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Nevro (NVRO), Integra Lifesciences (IART), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Inovio Pharmaceuticals (INO), AtriCure (ATRC), Glaukos (GKOS), Cantel Medical (CMD) and Luminex (LMNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), salesforce.com (CRM), Alibaba Group (BABA), Walt Disney (DIS), Trade Desk (TTD), Roku (ROKU), Paypal (PYPL), Square (SQ), Twilio (TWLO) and Shopify (SHOP).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shockwave Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (6.29%), BlackRock Inc. (4.76%), JPMorgan Chase & Co. (4.44%), Alpine Global Management LLC (4.17%), Wells Fargo & Company MN (3.59%) and Jennison Associates LLC (1.81%). Company insiders that own Shockwave Medical stock include Antoine Papiernik, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr. View institutional ownership trends for Shockwave Medical.

SWAV stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Balyasny Asset Management LLC, UBS Group AG, Morgan Stanley, Redmile Group LLC, Jennison Associates LLC, Legal & General Group Plc, and American International Group Inc.. Company insiders that have sold Shockwave Medical company stock in the last year include Antoine Papiernik, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, and Sofinnova Capital Vii Fcpr. View insider buying and selling activity for Shockwave Medical.

SWAV stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Wellington Management Group LLP, Alpine Global Management LLC, JPMorgan Chase & Co., AXA, BlackRock Inc., Aviva PLC, and Copernicus Capital Management LLC. View insider buying and selling activity for Shockwave Medical.

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SWAV stock can currently be purchased for approximately $44.11.

Shockwave Medical has a market capitalization of $1.41 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Shockwave Medical employs 162 workers across the globe.

The official website for Shockwave Medical is www.shockwavemedical.com.

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]